CD8A and melanoma: However, in a B16- OVA melanoma model, the encapsulated archaeosomes appeared to have a greater ability to activate CD8+ T cells by dendritic cells in vitro than admixed formulations, yet in an in vivo murine tumor model the activity of both formulations was comparable with respect to survival (16).